QURE实时信号 | 通过Getagraph.com最大化利润

购买 107484 min ago

@ $5.35

发出时间: 15 Feb 2024 @ 01:06

回报率: -15.25%

上一信号: Feb 14 - 00:21

上一信号: 出售

回报率: -4.81 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	343 044
平均成交量	949 696
市值	219.88M
EPS	$0 ( 2024-02-26 )
下一个收益日期	( $-1.310 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.700
ATR14	$0.00500 (0.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Kapusta Matthew C	Buy	150 000	Ordinary Shares
2024-03-01	Kapusta Matthew C	Buy	259 500	Stock Option (Right to Buy)
2024-03-01	Klemt Christian	Buy	49 500	Ordinary Shares
2024-03-01	Klemt Christian	Buy	85 500	Stock Option (Right to Buy)
2024-03-01	Abi-saab Walid	Buy	49 500	Ordinary Shares

INSIDER POWER
73.81
Last 98 transactions
Buy: 2 008 230 \| Sell: 329 878

音量相关性

長: -0.34 (neutral)

短: -0.78 (moderate negative)

Signal:(30.79) Neutral

Uniqure NV 相关性

10 最正相关
LWAC	0.93
SRAC	0.873
AMRB	0.864
NETE	0.839
ACER	0.823
MMAC	0.807
MRCC	0.806

10 最负相关
SVAC	-0.87
TLGT	-0.844
RCM	-0.833
ASTS	-0.832
RMRM	-0.824
LUNG	-0.82
TEAM	-0.805
MTSL	-0.804

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Uniqure NV 相关性 - 货币/商品

-0.72
( moderate negative )

-0.70
( moderate negative )

0.00
( neutral )

0.24
( neutral )

-0.10
( neutral )

Uniqure NV 财务报表

Annual	2023
营收:	$15.84M
毛利润:	$2.22M (13.98 %)
EPS:	$-6.47

FY	2023
营收:	$15.84M
毛利润:	$2.22M (13.98 %)
EPS:	$-6.47

FY	2022
营收:	$106.48M
毛利润:	$103.14M (96.86 %)
EPS:	$-2.71

FY	2021
营收:	$524.00M
毛利润:	$499.03M (95.23 %)
EPS:	$7.17

Financial Reports:

No articles found.

Uniqure NV

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.